This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Twenty-three years ago, the field of genetherapy was bursting with the promise of breakthrough treatments. Then it was almost instantly derailed by the death of an 18-year-old clinicaltrial volunteer named Jesse Gelsinger after he received a geneticallyengineered virus that had been developed to treat his rare liver condition.
Recombinant DNA technologies and genetically modified biological agents are being adapted for a wide scope of therapeutic applications, and their use is becoming increasingly common in clinicaltrials. How can I protect myself from exposure? What should I do if I’m exposed?
As Nick Spittal states in this Advarra press release, membership in the GeneTherapy Ready (GTR) site network “allows Velocity to start studies over a month faster and provides a meaningful credential and important validation that increases sponsors’ confidence in our specialized capabilities to conduct complex clinical research safely.”
Biopharmaceutical contract development and manufacturing organisation (CDMO) AGC Biologics has entered a strategic collaboration with RoosterBio to expedite the manufacturing of cell and exosome therapies. These capabilities comprise cell and exosome geneticengineering for expressing therapeutic targets.
Research in genetherapies and geneticallyengineered drugs and vaccines are growing exponentially, and will only continue to become more popular. The accelerating genetherapy market is expected to grow globally by 16.6% between 2020-2027.
Genetherapy research is booming in the clinical setting. In this blog, we summarize the growth, risks, and regulatory requirements for genetherapy research. Defining the Boom in GeneTherapy Research The genetherapy field is experiencing explosive growth in today’s competitive research environment.
But while companies continue studying allogeneic CAR-T therapies, including for their coveted use in solid tumours, such advancements remain challenging. More broadly however, several advancements are on the horizon for cell and genetherapies in 2023. AZ: Cell and genetherapies often come with a high price.
Rapid growth in genetherapy is expected to receive additional support as the Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) prepares to launch Operation Warp Speed for Rare Diseases. Peter Marks, head of FDA’s CBER – the organization responsible for regulating genetherapies.
The use of engineeredgenetic materials in clinicaltrials is rapidly expanding, with potential applications for genetic vaccines, gene-modified cellular therapies, and genetherapies.
The new year began with a fairly low level of clinicaltrial news. Arcturus Therapeutics got the FDA go-ahead for its Phase II trial of its COVID-19 vaccine candidate ARCT-021. The trial will enroll 600 participants, with 450 receiving ARCT-021 and 150 receiving placebo. FBX-101 is a first-in-human AAV genetherapy.
Personalized medicine using genetic resequencing techniques, such as cell and genetherapies, enables researchers to create more customized therapies for combatting cancer. Adoptive T Cell Therapies Adoptive T cell therapy is another form of cancer treatment leveraging the patient’s immune system.
The applications of gene switch platforms can be broadly classified into the following two categories: Endogenous Gene Regulation Exogenous Gene Regulation Endogenous Gene Regulation The ability to regulate endogenous genes has various applications in biological research and genetherapy development.
CAR-T Cells Target Harmful B Cells in Lupus CAR-T cell technology, which uses geneticengineering to direct white blood cells to attack specific molecular targets, was originally proposed for treatment of HIV infection and hematological malignancies. WCG has many ways to support cell and genetherapyclinicaltrials for lupus.
While developing an entirely new class of antibiotic is challenging, making minor genetic modifications to a virus or phage is something fairly easily accomplished with modern technologies. Intra-venous delivery of phages has potential as therapeutics for a broad range of conditions caused by antibiotic-resistant E.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content